Table VI.

Comparison of differences in Short Form-36 scores during and folowing daclatasvir/asunaprevir therapy according to age.

Group	Measure	Age <70	Age ≥70	P-value
Baseline-12 weeks	PF	−5.00±17.75	8.79±15.22	<0.05
	RP	−5.00±39.06	3.31±15.80	0.44
	BP	−3.09±31.45	3.64±23.31	0.58
	GH	−1.00±15.97	7.66±12.90	0.14
	VT	0.57±23.79	1.59±12.00	0.88
	SF	−4.55±32.73	−5.15±22.56	0.95
	RE	−5.83±39.49	−1.47±13.89	0.68
	MH	−5.57±25.90	4.49±9.75	0.16
Baseline-EOT	PF	−6.82±23.16	1.27±21.42	0.35
	RP	−11.93±43.79	2.94±16.55	0.21
	BP	−14.27±37.50	4.06±21.79	0.11
	GH	−1.09±12.80	9.44±13.47	0.05
	VT	7.95±23.06	1.56±15.73	0.40
	SF	−5.68±33.71	−1.47±21.14	0.69
	RE	−3.03±39.66	1.96±9.56	0.62
	MH	−0.11±24.22	2.89±12.13	0.67
Baseline-SVR24	PF	−9.00±29.61	−4.05±24.39	0.64
	RP	−10.62±36.09	−1.84±21.74	0.44
	BP	1.00±29.58	−8.65±21.84	0.33
	GH	−0.73±12.15	9.91±16.93	0.08
	VT	6.82±25.69	0.74±14.13	0.43
	SF	−4.55±28.65	−12.50±18.75	0.38
	RE	2.27±40.84	−2.45±21.60	0.69
	MH	−3.30±20.87	−2.21±17.67	0.88

Data are expressed as the mean ± standard deviation. Data analyses were performed using the Student's t-test. DCV/ASV, daclatasvir/asunaprevir; 12 weeks, following 12 weeks of DCV/ASV therapy; EOT, the end of treatment; SVR24, sustained virologic response week 24; PF, physical functioning; RP, physical role functioning; BP, bodily pain; GH, general health; VT, vitality; SF, social role functioning; RE, emotional role functioning; MH, mental health.